Amphastar Pharmaceuticals Inc (AMPH) Shares Sold by Millennium Management LLC

Millennium Management LLC reduced its stake in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 11.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,520 shares of the company’s stock after selling 5,106 shares during the quarter. Millennium Management LLC owned about 0.08% of Amphastar Pharmaceuticals worth $588,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMPH. Piedmont Investment Advisors LLC bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $128,000. Meeder Asset Management Inc. grew its stake in shares of Amphastar Pharmaceuticals by 259.8% during the second quarter. Meeder Asset Management Inc. now owns 10,486 shares of the company’s stock valued at $160,000 after purchasing an additional 7,572 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $161,000. Cubist Systematic Strategies LLC bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $295,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $387,000. 42.86% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ AMPH opened at $21.59 on Friday. Amphastar Pharmaceuticals Inc has a fifty-two week low of $14.40 and a fifty-two week high of $21.65. The company has a market capitalization of $890.44 million, a P/E ratio of 56.82, a price-to-earnings-growth ratio of 8.77 and a beta of 1.38. The company has a current ratio of 1.94, a quick ratio of 1.24 and a debt-to-equity ratio of 0.11.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Thursday, November 8th. The company reported $0.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. The business had revenue of $75.54 million for the quarter, compared to analyst estimates of $76.84 million. During the same period in the prior year, the business posted $0.07 earnings per share. Amphastar Pharmaceuticals’s revenue was up 30.5% compared to the same quarter last year. Research analysts predict that Amphastar Pharmaceuticals Inc will post 0.1 EPS for the current fiscal year.

AMPH has been the topic of several analyst reports. Needham & Company LLC set a $25.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a report on Friday. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. BidaskClub lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. Wells Fargo & Co restated a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Friday. Finally, ValuEngine upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 17th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Amphastar Pharmaceuticals has an average rating of “Buy” and an average price target of $23.00.

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 2,407 shares of the stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $17.59, for a total value of $42,339.13. Following the sale, the chief financial officer now directly owns 86,836 shares in the company, valued at $1,527,445.24. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Richard K. Prins sold 10,000 shares of the stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $17.82, for a total transaction of $178,200.00. The disclosure for this sale can be found here. Insiders sold 28,502 shares of company stock worth $558,373 over the last 90 days. 31.50% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Amphastar Pharmaceuticals Inc (AMPH) Shares Sold by Millennium Management LLC” was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.wkrb13.com/2018/11/10/amphastar-pharmaceuticals-inc-amph-shares-sold-by-millennium-management-llc.html.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Recommended Story: NASDAQ

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply